Skip to main content

Table 2 Numbers of events and 2-year and 5-year disease-free survival (DFS) and overall survival (OS) relative to treatment arm (95% confidence intervals in brackets)

From: Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial

  FEC → Doc FEC → Doc/Gem
DFS
 Events 239 219
 2-year rate 0.95 (0.94, 0.96) 0.95 (0.94, 0.96)
 5-year rate 0.87 (0.85, 0.88) 0.87 (0.86, 0.89)
OS
 Events 140 129
 2-year rate 0.98 (0.97, 0.99) 0.98 (0.97, 0.98)
 5-year rate 0.93 (0.92, 0.94) 0.93 (0.91, 0.94)